Search
Spotlight
The OncLive Insider app is live!
CME Opportunities
The OncLive Insider app is live!
CME Opportunities
Specialty
View More
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
News
OncClub
All Oncology News
OncClub
All Oncology News
Media
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Conferences
Conference Coverage
Conference Listing
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Partners
Publications
Resources
Consensus Viewpoints
OncLive App
Interactive Tools
Sponsored
Consensus Viewpoints
OncLive App
Interactive Tools
Sponsored
Biomarker Consortium
Subscribe
Search
Spotlight
The OncLive Insider app is live!
CME Opportunities
Specialty
See All >
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Immuno-Oncology | Specialty
home
Content Type
Key Takeaway 5: Dosing of Multiple Kinase Inhibitors
September 16th 2019
Key Takeaway 4: Right-Sided Tumors: Anti-Angiogenic Treatment
September 16th 2019
Key Takeaway 3: Determining Tumor Mutational Status
September 16th 2019
Key Takeaway 2: Frontline Neoadjuvant Chemotherapy
September 16th 2019
Key Takeaway 1: Adjuvant Therapy Optimal Duration
September 16th 2019
Novel Lung Cancer Therapy: Future Improvements and Challenges
September 6th 2019
MET as a Clinical Target in Lung Cancer
September 6th 2019
Expanding the NSCLC Armamentarium: IMpower131
September 6th 2019
Extensive-Stage SCLC: Potential in the CASPIAN Trial
September 6th 2019
Targeted Therapy for KRAS p.G12C NSCLC
September 6th 2019
Future Directions in Lung Cancer Management
September 6th 2019
Metastatic NSCLC: Interpreting Data From NEPTUNE
September 6th 2019
Updated Data in Stage IV NSCLC: CheckMate-227
September 6th 2019
LIBRETTO-001: Targeting RET Fusions in Advanced-Stage NSCLC
September 6th 2019
Advanced-Stage NSCLC: Overall Survival Data From FLAURA
September 6th 2019
Overview of Novel Therapy for Advanced-Stage NSCLC
September 6th 2019
Key Takeaway 6: Role of Immunotherapy in R/R mHCC
August 15th 2019
Key Takeaway 5: High AFP is a Biomarker for Ramucirumab
August 15th 2019
Key Takeaway 4: Second-Line Regorafenib After TKI in HCC
August 15th 2019
Key Takeaway 3: Role of Frontline I/O Still Pending
August 15th 2019
NEXT PAGE
<
1
...
51
52
53
54
55
56
57
58
59
...
203
>
PREVIOUS PAGE